Insmed is a global biopharmaceutical company focused on the needs of patients with rare diseases. Headquartered in Bridgewater, NJ, Insmed is a dynamic and rapidly growing company with a strong pipeline of drug candidates. Patients who suffer from rare diseases, such as nontuberculous mycobacteria (NTM) lung disease and pulmonary arterial hypertension (PAH), face multiple hurdles in finding effective treatments. Insmed is addressing the critical, unmet needs of these orphan patient populations. The company’s lead product candidate is an inhaled antibiotic that is in late-stage clinical development for serious lung infections caused by NTM. There are currently no approved therapies in the United States or European Union for NTM lung disease. “Insmed is a team of talented and motivated professionals who are dedicated to making a difference in the lives of patients with rare diseases, said Will Lewis, president and CEO at Insmed. “Patients are at the center of everything we do and each of us brings a personal passion for advancing innovative therapies that can transform the lives of patients with rare diseases around the world.” The company is also developing INS1009, a nebulized treprostinil prodrug for the treatment of PAH. Insmed’s innovative focus is on the convenient dosing regimen, enhanced drug delivery, and lower systemic drug exposure which exemplifies its priority to improve patient comfort and care.
Show more
Bridgewater, US
Size (employees)
161 (est)
Insmed is headquartered in Bridgewater, US
Report incorrect company information

Key People/Management at Insmed

Kevin P. Tully

Kevin P. Tully

Evp & CFO
Steinar Engelsen

Steinar Engelsen

Member of the Board of Directors
Show more

Insmed Office Locations

Insmed has offices in Dublin, London, Bridgewater, Amsterdam and in 3 other locations
Bridgewater, US (HQ)
10 Finderne Ave
Paris, FR
1 Rue Favart
Frankfurt am Main, DE
49 Mainzer Landstraße
Dublin, IE
28 N Wall Quay
Amsterdam, NL
201 Barbara Strozzilaan
Utrecht, NL
328 Graadt van Roggenweg
Show all (7)
Report incorrect company information

Insmed Financials and Metrics

Insmed Revenue

Insmed's revenue was reported to be $11.50 m in FY, 2013

Net income (Q1, 2018)

(68.5 m)

EBIT (Q1, 2018)

(62.8 m)

Market capitalization (18-Jul-2018)

1.9 b

Closing share price (18-Jul-2018)


Cash (31-Mar-2018)

686.6 m


1.6 b
Insmed's current market capitalization is $1.9 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016


11.5 m

Revenue growth, %


General and administrative expense

50.7 m

R&D expense

122.7 m
USDQ3, 2013Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

General and administrative expense

4.7 m7.9 m8.2 m9.5 m9.7 m11 m12.5 m12.3 m13.7 m13.7 m16.6 m17.4 m32.7 m

R&D expense

12.1 m14.9 m15.2 m17.2 m18.2 m19.2 m20.5 m23.9 m23.4 m22.3 m26.9 m26.7 m30.1 m

Operating expense total

16.8 m22.8 m23.4 m26.7 m28 m30.2 m33.1 m36.1 m37.1 m36 m43.5 m44.1 m62.8 m


(16.8 m)(22.8 m)(23.4 m)(26.7 m)(28 m)(30.2 m)(33.1 m)(36.1 m)(37.1 m)(36 m)(43.5 m)(44.1 m)(62.8 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016


113.9 m159.2 m282.9 m162.6 m

Accounts Receivable

39.3 m


2.3 m5.5 m5.2 m5.8 m

Current Assets

116.2 m164.7 m288.1 m168.4 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018


128 m101.3 m82.7 m167.3 m134.6 m335 m311 m252.9 m223.1 m200.5 m125.8 m91.1 m430.7 m686.6 m

Current Assets

129.7 m106.2 m86.7 m170.8 m140.2 m342.1 m319.3 m258.5 m229.3 m206.3 m131.6 m96.5 m437.5 m696.4 m


15.8 m

Total Assets

190 m166.6 m150.1 m235.4 m206.2 m408.5 m385.7 m327.7 m299.7 m276.6 m200.7 m165.6 m506.2 m773.2 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(56.1 m)(79.2 m)(118.2 m)(176.3 m)

Depreciation and Amortization

680 k1.1 m2 m2.4 m

Accounts Payable

(1.1 m)3.3 m(1.8 m)2.8 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Net Income

(39.9 m)(14.3 m)(37.5 m)(61.5 m)(27.4 m)(56 m)(86.9 m)(33.5 m)(70.1 m)(107.9 m)(37.4 m)(82.1 m)(127.3 m)(68.5 m)

Depreciation and Amortization

475 k167 k342 k697 k432 k879 k1.3 m514 k1.1 m1.8 m716 k1.5 m2.2 m769 k

Accounts Payable

(2.4 m)3.9 m3.6 m2.5 m(1.4 m)(981 k)1.3 m527 k1.2 m361 k(2 m)767 k(921 k)(828 k)

Cash From Operating Activities

(32.6 m)(12.6 m)(30.6 m)(51.5 m)(24.9 m)(49.1 m)(73.2 m)(29.5 m)(57.8 m)(88.7 m)(36.9 m)(73.2 m)(111.4 m)(68 m)
USDY, 2018


-24.9 x


-23 x

Financial Leverage

1.8 x
Show all financial metrics
Report incorrect company information

Insmed Company Life and Culture

Report incorrect company information